Bubble continuous positive airway pressure (CPAP) is a widely used non-invasive respiratory support strategy for neonates and is commonly employed in the management of preterm infants with respiratory distress. Bubble CPAP generates continuous distending pressure by submerging the distal expiratory limb in water, producing low-amplitude, high-frequency pressure oscillations as airflow escapes and bubbles into the water canister. These oscillations, which are transmitted back to the neonate, vary dynamically with airway and lung mechanics and may contribute to the physiological benefits observed with bubble CPAP. This review summarizes the historical context, physiological rationale, clinical evidence supporting bubble CPAP, and areas for future optimization.
{"title":"Bubble CPAP in neonatal care: mechanisms, evidence, and pathways to optimization.","authors":"Amanda Gross, Emily R Campbell, Lidiaine Oliveira, Guilherme Sant'Anna, Wissam Shalish","doi":"10.1016/j.prrv.2025.12.004","DOIUrl":"https://doi.org/10.1016/j.prrv.2025.12.004","url":null,"abstract":"<p><p>Bubble continuous positive airway pressure (CPAP) is a widely used non-invasive respiratory support strategy for neonates and is commonly employed in the management of preterm infants with respiratory distress. Bubble CPAP generates continuous distending pressure by submerging the distal expiratory limb in water, producing low-amplitude, high-frequency pressure oscillations as airflow escapes and bubbles into the water canister. These oscillations, which are transmitted back to the neonate, vary dynamically with airway and lung mechanics and may contribute to the physiological benefits observed with bubble CPAP. This review summarizes the historical context, physiological rationale, clinical evidence supporting bubble CPAP, and areas for future optimization.</p>","PeriodicalId":19658,"journal":{"name":"Paediatric Respiratory Reviews","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-26DOI: 10.1016/j.prrv.2025.12.003
Catharina Tao, Mary Fortune, Emma A Webb, Theofilos Polychronakis
Background: Obstructive sleep apnoea (OSA) is prevalent among children with obesity and is associated with long-term morbidity.
Methods: We conducted a systematic review and meta-analysis of risk factors for OSA among children (0-18) who are overweight/obese. Risk factors reviewed included overall adiposity, regional fat distribution, adenotonsillar hypertrophy, sex, ethnicity, and airway neuromuscular tone. PubMed and Embase were searched in July 2025. Random-effects models were applied.
Results: Forty-seven studies were included. Children with OSA had higher BMI z-scores (mean difference (MD) = 0.30), neck circumference (MD = 2.19 cm), and waist circumference (MD = 5.99 cm) compared to obese children without OSA. Adenotonsillar hypertrophy and male sex associated with higher OSA odds (adenoid odds ratio (OR) = 3.28, tonsil OR = 4.16, Male OR = 1.51). Studies also suggested airway neuromuscular tone and non-Caucasian ethnicity as risk factors, but further research is needed.
Conclusion: OSA in obese children is likely to be multifactorial. Assessment accounting for multiple factors may improve screening accuracy and guide targeted interventions in this high-risk population.
{"title":"Risk factors for obstructive sleep apnoea in obese children: a systematic review and meta-analysis.","authors":"Catharina Tao, Mary Fortune, Emma A Webb, Theofilos Polychronakis","doi":"10.1016/j.prrv.2025.12.003","DOIUrl":"https://doi.org/10.1016/j.prrv.2025.12.003","url":null,"abstract":"<p><strong>Background: </strong>Obstructive sleep apnoea (OSA) is prevalent among children with obesity and is associated with long-term morbidity.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis of risk factors for OSA among children (0-18) who are overweight/obese. Risk factors reviewed included overall adiposity, regional fat distribution, adenotonsillar hypertrophy, sex, ethnicity, and airway neuromuscular tone. PubMed and Embase were searched in July 2025. Random-effects models were applied.</p><p><strong>Results: </strong>Forty-seven studies were included. Children with OSA had higher BMI z-scores (mean difference (MD) = 0.30), neck circumference (MD = 2.19 cm), and waist circumference (MD = 5.99 cm) compared to obese children without OSA. Adenotonsillar hypertrophy and male sex associated with higher OSA odds (adenoid odds ratio (OR) = 3.28, tonsil OR = 4.16, Male OR = 1.51). Studies also suggested airway neuromuscular tone and non-Caucasian ethnicity as risk factors, but further research is needed.</p><p><strong>Conclusion: </strong>OSA in obese children is likely to be multifactorial. Assessment accounting for multiple factors may improve screening accuracy and guide targeted interventions in this high-risk population.</p>","PeriodicalId":19658,"journal":{"name":"Paediatric Respiratory Reviews","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145944648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-24DOI: 10.1016/j.prrv.2025.12.001
Dinh Son Bui, Cassidy Du Berry, Nur Sabrina Idrose, Jeanie L Y Cheong, Shyamali Dharmage
Preterm birth is increasingly recognised as a major determinant of lifelong respiratory health. Longitudinal studies consistently demonstrate that individuals born preterm have persistently worse lung function from childhood to adulthood compared with their term born peers. These adverse effects vary across gestational categories including extremely preterm, very preterm and moderate-late preterm birth, and are further exacerbated by bronchopulmonary dysplasia (BPD). Pooled analyses show that children or adults born preterm without BPD had 7.2% [95 confidence interval (CI): 5.6-8.7%] lower percent predicted FEV1 than term-born individuals. The %FEV1 deficit was greater in those with BPD: 18.9% [16.7-21.1%] lower for the BPD36 group when compared with the term born group. Lung function deficits in pre-term born survivors persist into adult life. Preterm birth is also associated with increased risk of COPD in later life. There is evidence that male sex confers additional vulnerability in pre-term survivors, with recent literature showing poorer lung function in males compared with females. Understanding these relationships is central to developing future phenotyping frameworks, enabling early identification of those at greatest risk, and informing surveillance strategies aimed at preserving lung function and preventing early onset of chronic obstructive pulmonary disease.
{"title":"Lung trajectories into adulthood of preterm born survivors and the influence of sex.","authors":"Dinh Son Bui, Cassidy Du Berry, Nur Sabrina Idrose, Jeanie L Y Cheong, Shyamali Dharmage","doi":"10.1016/j.prrv.2025.12.001","DOIUrl":"https://doi.org/10.1016/j.prrv.2025.12.001","url":null,"abstract":"<p><p>Preterm birth is increasingly recognised as a major determinant of lifelong respiratory health. Longitudinal studies consistently demonstrate that individuals born preterm have persistently worse lung function from childhood to adulthood compared with their term born peers. These adverse effects vary across gestational categories including extremely preterm, very preterm and moderate-late preterm birth, and are further exacerbated by bronchopulmonary dysplasia (BPD). Pooled analyses show that children or adults born preterm without BPD had 7.2% [95 confidence interval (CI): 5.6-8.7%] lower percent predicted FEV<sub>1</sub> than term-born individuals. The %FEV<sub>1</sub> deficit was greater in those with BPD: 18.9% [16.7-21.1%] lower for the BPD<sub>36</sub> group when compared with the term born group. Lung function deficits in pre-term born survivors persist into adult life. Preterm birth is also associated with increased risk of COPD in later life. There is evidence that male sex confers additional vulnerability in pre-term survivors, with recent literature showing poorer lung function in males compared with females. Understanding these relationships is central to developing future phenotyping frameworks, enabling early identification of those at greatest risk, and informing surveillance strategies aimed at preserving lung function and preventing early onset of chronic obstructive pulmonary disease.</p>","PeriodicalId":19658,"journal":{"name":"Paediatric Respiratory Reviews","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145952176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-18DOI: 10.1016/j.prrv.2025.12.002
Nicola Collins, Caroline Devon, Siân Bentley, Emma Dixon, Delyth Jones, Suzie Kenny, Sukeshi Makhecha, Sarah Moledina, Nicola Murray, Michèle Puckey, Chloe Worger, Ian M Balfour-Lynn
This paper reviews the use of home intravenous antibiotics (IVABs) in children with cystic fibrosis (CF). We outline a program we developed during the COVID-19 pandemic for enhancing the experience for children and families by involving full multidisciplinary follow up via video for the duration of the antibiotic course. We did find though, that the majority of families were unsuitable for home IVABs. We hope that this information will be useful for other CF units considering setting up a hospital at home service.
{"title":"Home intravenous antibiotics for cystic fibrosis - setting up a hospital @home service.","authors":"Nicola Collins, Caroline Devon, Siân Bentley, Emma Dixon, Delyth Jones, Suzie Kenny, Sukeshi Makhecha, Sarah Moledina, Nicola Murray, Michèle Puckey, Chloe Worger, Ian M Balfour-Lynn","doi":"10.1016/j.prrv.2025.12.002","DOIUrl":"https://doi.org/10.1016/j.prrv.2025.12.002","url":null,"abstract":"<p><p>This paper reviews the use of home intravenous antibiotics (IVABs) in children with cystic fibrosis (CF). We outline a program we developed during the COVID-19 pandemic for enhancing the experience for children and families by involving full multidisciplinary follow up via video for the duration of the antibiotic course. We did find though, that the majority of families were unsuitable for home IVABs. We hope that this information will be useful for other CF units considering setting up a hospital at home service.</p>","PeriodicalId":19658,"journal":{"name":"Paediatric Respiratory Reviews","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145864403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-02-07DOI: 10.1016/j.prrv.2025.02.001
Curtis Budden , Loredana Cuglietta , Amir Sadri
Robin sequence (RS) is diagnosed by the clinical triad of micrognathia, glossoptosis, and airway obstruction. The reported occurrence is variable and noted in 1:8,500 to 1:20,000 live births. Although advances in perinatal imaging, neonatal resuscitation, non-invasive respiratory support and surgical techniques can mitigate against adverse outcomes, there remains much debate as to the best treatment for children born with RS. This review will outline surgical treatment of cleft palate and speech outcomes for children with RS.
{"title":"Cleft palate surgery and speech outcomes in children with Robin sequence","authors":"Curtis Budden , Loredana Cuglietta , Amir Sadri","doi":"10.1016/j.prrv.2025.02.001","DOIUrl":"10.1016/j.prrv.2025.02.001","url":null,"abstract":"<div><div><span>Robin sequence (RS) is diagnosed by the clinical triad of micrognathia<span>, glossoptosis, and airway obstruction. The reported occurrence is variable and noted in 1:8,500 to 1:20,000 live births. Although advances in perinatal imaging, </span></span>neonatal resuscitation<span><span>, non-invasive respiratory support and surgical techniques can mitigate against </span>adverse outcomes, there remains much debate as to the best treatment for children born with RS. This review will outline surgical treatment of cleft palate and speech outcomes for children with RS.</span></div></div>","PeriodicalId":19658,"journal":{"name":"Paediatric Respiratory Reviews","volume":"56 ","pages":"Pages 55-60"},"PeriodicalIF":4.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-07-25DOI: 10.1016/j.prrv.2025.07.001
Dominic A. Fitzgerald , Hannah North
{"title":"Editorial: Overlooked and underdone: Treatment of ear and nasal problems in children","authors":"Dominic A. Fitzgerald , Hannah North","doi":"10.1016/j.prrv.2025.07.001","DOIUrl":"10.1016/j.prrv.2025.07.001","url":null,"abstract":"","PeriodicalId":19658,"journal":{"name":"Paediatric Respiratory Reviews","volume":"56 ","pages":"Pages 1-2"},"PeriodicalIF":4.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-26DOI: 10.1016/j.prrv.2025.10.003
Nichkamol Lertamornkitti , Philip N. Britton
Measles is an important vaccine-preventable disease that has re-emerged in recent years. Since the COVID-19 pandemic, interruptions to routine immunisation programs and declining vaccine coverage have altered the incidence and patterns of respiratory virus infections. Global outbreaks have intensified, and vaccine hesitancy is recognised as major health threat. Revisiting the clinical presentation of measles is crucial for early diagnosis and to reduce transmission of this highly contagious infection. As serious respiratory and neurological complications can follow natural infection and no specific antiviral therapy is available, vaccination remains the most effective strategy for prevention and control.
{"title":"Measles is misery: A brief update for paediatricians","authors":"Nichkamol Lertamornkitti , Philip N. Britton","doi":"10.1016/j.prrv.2025.10.003","DOIUrl":"10.1016/j.prrv.2025.10.003","url":null,"abstract":"<div><div>Measles is an important vaccine-preventable disease that has re-emerged in recent years. Since the COVID-19 pandemic, interruptions to routine immunisation programs and declining vaccine coverage have altered the incidence and patterns of respiratory virus infections. Global outbreaks have intensified, and vaccine hesitancy is recognised as major health threat. Revisiting the clinical presentation of measles is crucial for early diagnosis and to reduce transmission of this highly contagious infection. As serious respiratory and neurological complications can follow natural infection and no specific antiviral therapy is available, vaccination remains the most effective strategy for prevention and control.</div></div>","PeriodicalId":19658,"journal":{"name":"Paediatric Respiratory Reviews","volume":"56 ","pages":"Pages 24-28"},"PeriodicalIF":4.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145513396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-03-03DOI: 10.1016/j.prrv.2025.02.003
Aluisio D’lucas Alves Gomes , Elísio Bulhões , Danielle Costa do Amaral , Luis Felipe Matos de Sousa , Ely Cavalcante Lima Júnior , José Airton Alves Ferreira , Hilderlania Alves de Oliveira , Maria LR Defante , Jafar Aljazeeri
Background
Bronchopulmonary dysplasia (BPD) is a chronic pulmonary disease commonly affecting preterm infants. The potential benefits of combining budesonide with surfactant for preterms with early BPD remain uncertain and warrant further exploration.
Objective
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of intratracheal budesonide plus surfactant compared with surfactant alone in preterm infants.
Methods
We searched PubMed, Embase and Cochrane Central databases from inception to November 2024. We conducted a meta-analysis following the PRISMA guidelines. We calculated the risk ratios (RRs) of endpoints of interest with 95% confidence intervals using a random effects model. R software (version 4.3.2) was used for statistical analyses. Heterogeneity was assessed with I2 statistics.
Results
Eight RCTs including 2029 preterm infants were included. Compared with surfactant alone, a combined intratracheal budesonide plus surfactant significantly reduced the risk of bronchopulmonary dysplasia (RR: 0.70; 95 % CI: 0.54–0.91; p = 0.007; I2 = 71.4 %), mortality (RR: 0.81; 95 % CI: 0.66–0.98; p = 0.029; I2 = 14.6 %), pulmonary hemorrhage (RR: 0.58; 95 % CI: 0.37–0.90; p = 0.015; I2 = 0 %) and patent ductus arteriosus (RR: 0.84; 95 % CI: 0.75–0.94; p = 0.004; I2 = 0 %).
Conclusion
This meta-analysis found that intratracheal budesonide plus surfactant reduces the risk of bronchopulmonary dysplasia, mortality, pulmonary hemorrhage and patent ductus arteriosus compared with surfactant alone. Given its potential to reduce pulmonary complications associated with prematurity, clinicians may consider this combination therapy.
{"title":"Efficacy of intratracheal budesonide plus surfactant vs. Surfactant alone on bronchopulmonary dysplasia in preterm Infants: A meta-analysis of randomized controlled trials","authors":"Aluisio D’lucas Alves Gomes , Elísio Bulhões , Danielle Costa do Amaral , Luis Felipe Matos de Sousa , Ely Cavalcante Lima Júnior , José Airton Alves Ferreira , Hilderlania Alves de Oliveira , Maria LR Defante , Jafar Aljazeeri","doi":"10.1016/j.prrv.2025.02.003","DOIUrl":"10.1016/j.prrv.2025.02.003","url":null,"abstract":"<div><h3>Background</h3><div><span><span>Bronchopulmonary dysplasia (BPD) is a </span>chronic pulmonary disease commonly affecting preterm infants. The potential benefits of combining </span>budesonide with surfactant for preterms with early BPD remain uncertain and warrant further exploration.</div></div><div><h3>Objective</h3><div><span>We conducted a systematic review and </span><em>meta</em><span>-analysis of randomized controlled trials<span> (RCTs) to evaluate the efficacy of intratracheal budesonide plus surfactant compared with surfactant alone in preterm infants.</span></span></div></div><div><h3>Methods</h3><div>We searched PubMed, Embase and Cochrane Central databases from inception to November 2024. We conducted a <em>meta</em>-analysis following the PRISMA guidelines. We calculated the risk ratios (RRs) of endpoints of interest with 95% confidence intervals using a random effects model. R software (version 4.3.2) was used for statistical analyses. Heterogeneity was assessed with I<sup>2</sup> statistics.</div></div><div><h3>Results</h3><div>Eight RCTs including 2029 preterm infants were included. Compared with surfactant alone, a combined intratracheal budesonide plus surfactant significantly reduced the risk of bronchopulmonary dysplasia (RR: 0.70; 95 % CI: 0.54–0.91; p = 0.007; I<sup>2</sup> = 71.4 %), mortality (RR: 0.81; 95 % CI: 0.66–0.98; p = 0.029; I<sup>2</sup><span> = 14.6 %), pulmonary hemorrhage (RR: 0.58; 95 % CI: 0.37–0.90; p = 0.015; I</span><sup>2</sup><span> = 0 %) and patent ductus arteriosus (RR: 0.84; 95 % CI: 0.75–0.94; p = 0.004; I</span><sup>2</sup> = 0 %).</div></div><div><h3>Conclusion</h3><div>This <em>meta</em><span>-analysis found that intratracheal budesonide plus surfactant reduces the risk of bronchopulmonary dysplasia, mortality, pulmonary hemorrhage<span> and patent ductus arteriosus compared with surfactant alone. Given its potential to reduce pulmonary complications associated with prematurity, clinicians may consider this combination therapy.</span></span></div></div>","PeriodicalId":19658,"journal":{"name":"Paediatric Respiratory Reviews","volume":"56 ","pages":"Pages 68-74"},"PeriodicalIF":4.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Most children globally (~80%) are affected by Otitis Media with Effusion (OME; ‘serous otitis media’ or ‘glue ear’) by four years of age. Most episodes resolve in a timely manner are brief and uncomplicated. Chronic, recurrent and complicated OME has been linked to social disadvantage, with poorer educational and employment outcomes and increased criminal justice system contact. Specific populations are particularly at risk, even in High Income Countries, including children with craniofacial abnormalities, immunocompromise and First Nations children in colonised regions (e.g., Australia, New Zealand, and the Arctic Circle).
OME is a significant cause of childhood morbidity, particularly during infancy. Mortality should not occur in High-Income-Countries. However, in Low-Middle-Income Countries, lack of access to health programs can lead to devastating, preventable complications, including death from meningitis, brain abscesses, and sepsis. This emphasises the importance of equitable access to medical resources globally, a universal and ongoing problem for First Nations people.
Upper respiratory tract infections (including OME), are the most common reason for children to present to healthcare services, be prescribed antibiotics, and undergo surgery. Although OME is often managed by with antibiotics, guidelines recommend observation for uncomplicated cases, given potential harms for the child (e.g., rash and diarrhoea), and for healthcare (e.g., cost and antibiotic resistance). OME is also the most common reason for hearing impairment among children, and peaks at the time that auditory processing neural pathways, the foundations of cognitive development, are being laid down. Causative effect between OME and impaired cognitive function is hard to prove because of the challenges of designing and analysing rigorous observational studies to emulate clinical trials.
Recurrent OME cannot be left untreated due to the potential for its effect on hearing loss and both severe physical harm and significant long-term social consequences. Clinicians should be aware that children’s behavioural and developmental outcomes and balance disturbance may indicate middle ear disease or its sequelae and remain vigilant. Children’s ears should be checked and findings documented at every healthcare visit to ensure close surveillance for this insidious condition, particularly for those most at-risk.
{"title":"Glue ear: an ongoing global program – closing the audiology gap among First Nations children","authors":"Isabella Ludbrook , Georgia Tongs Wiradjuri , Kelvin Kong Worimi , Hasantha Gunasekera","doi":"10.1016/j.prrv.2025.04.011","DOIUrl":"10.1016/j.prrv.2025.04.011","url":null,"abstract":"<div><div>Most children globally (~80%) are affected by Otitis Media with Effusion (OME; ‘serous otitis media’ or ‘glue ear’) by four years of age. Most episodes resolve in a timely manner are brief and uncomplicated. Chronic, recurrent and complicated OME has been linked to social disadvantage, with poorer educational and employment outcomes and increased criminal justice system contact. Specific populations are particularly at risk, even in High Income Countries, including children with craniofacial abnormalities, immunocompromise and First Nations children in colonised regions (e.g., Australia, New Zealand, and the Arctic Circle).</div><div>OME is a significant cause of childhood morbidity, particularly during infancy. Mortality should not occur in High-Income-Countries. However, in Low-Middle-Income Countries, lack of access to health programs can lead to devastating, preventable complications, including death from meningitis, brain abscesses, and sepsis. This emphasises the importance of equitable access to medical resources globally, a universal and ongoing problem for First Nations people.</div><div>Upper respiratory tract infections (including OME), are the most common reason for children to present to healthcare services, be prescribed antibiotics, and undergo surgery. Although OME is often managed by with antibiotics, guidelines recommend observation for uncomplicated cases, given potential harms for the child (e.g., rash and diarrhoea), and for healthcare (e.g., cost and antibiotic resistance). OME is also the most common reason for hearing impairment among children, and peaks at the time that auditory processing neural pathways, the foundations of cognitive development, are being laid down. Causative effect between OME and impaired cognitive function is hard to prove because of the challenges of designing and analysing rigorous observational studies to emulate clinical trials.</div><div>Recurrent OME cannot be left untreated due to the potential for its effect on hearing loss and both severe physical harm and significant long-term social consequences. Clinicians should be aware that children’s behavioural and developmental outcomes and balance disturbance may indicate middle ear disease or its sequelae and remain vigilant. Children’s ears should be checked and findings documented at every healthcare visit to ensure close surveillance for this insidious condition, particularly for those most at-risk.</div></div>","PeriodicalId":19658,"journal":{"name":"Paediatric Respiratory Reviews","volume":"56 ","pages":"Pages 15-23"},"PeriodicalIF":4.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2024-11-01DOI: 10.1016/j.prrv.2024.10.004
Jose A. Castro-Rodriguez , Patricio Astudillo , Sandeep Puranik , Mark A. Brown , Adnan Custovic , Erick Forno
Viral bronchiolitis is the most common pediatric acute respiratory infection leading to hospitalization, and it causes a significant healthcare burden worldwide. Current guidelines recommend supportive management after many clinical trials on specific therapies failed to demonstrate benefits. However, several studies in the past decade have revealed that bronchiolitis may not be a homogeneous disease, but instead may constitute an umbrella comprised of different “endotypes” and “phenotypes” based on patient characteristics, etiology, pathophysiological mechanisms, and clinical presentation. In this extensive review, we summarize the current evidence that several different types of bronchiolitis (“bronchiolitides”) coexist, with different short- and long-term consequences on respiratory health and the risk of asthma development. Disease pathobiology, immune response, and clinical characteristics may differ between the two most prevalent viral agents, respiratory syncytial virus and rhinovirus. Recent randomized trials have shown that some subgroups of children may benefit from the use of systemic corticosteroids and/or bronchodilators. These findings also suggest that some children may benefit from individualized therapeutical approaches for viral bronchiolitis rather than following broad recommendations for treating all patients uniformly using only supportive management.
{"title":"New paradigms in acute viral bronchiolitis: Is it time to change our approach?","authors":"Jose A. Castro-Rodriguez , Patricio Astudillo , Sandeep Puranik , Mark A. Brown , Adnan Custovic , Erick Forno","doi":"10.1016/j.prrv.2024.10.004","DOIUrl":"10.1016/j.prrv.2024.10.004","url":null,"abstract":"<div><div><span><span><span><span>Viral bronchiolitis is the most common pediatric </span>acute respiratory infection leading to hospitalization, and it causes a significant healthcare burden worldwide. Current guidelines recommend supportive management after many </span>clinical trials on specific therapies failed to demonstrate benefits. However, several studies in the past decade have revealed that bronchiolitis may not be a homogeneous disease, but instead may constitute an umbrella comprised of different “endotypes” and “phenotypes” based on </span>patient characteristics<span>, etiology, pathophysiological mechanisms, and clinical presentation. In this extensive review, we summarize the current evidence that several different types of bronchiolitis (“bronchiolitides”) coexist, with different short- and long-term consequences on respiratory health and the risk of asthma development. Disease pathobiology, immune response, and clinical characteristics may differ between the two most prevalent viral agents, respiratory syncytial virus and </span></span>rhinovirus<span><span>. Recent randomized trials have shown that some subgroups of children may benefit from the use of systemic corticosteroids and/or </span>bronchodilators. These findings also suggest that some children may benefit from individualized therapeutical approaches for viral bronchiolitis rather than following broad recommendations for treating all patients uniformly using only supportive management.</span></div></div>","PeriodicalId":19658,"journal":{"name":"Paediatric Respiratory Reviews","volume":"56 ","pages":"Pages 29-36"},"PeriodicalIF":4.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142730969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}